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The relationship between blood pressure (BP) and clinical
outcomes among hemodialysis patients is complex and
incompletely understood. This study sought to assess the
relationship between blood pressure changes with
hemodialysis and clinical outcomes during a 6-month period.
This study is a secondary analysis of the Crit-Line Intradialytic
Monitoring Benefit Study, a randomized trial of 443
hemodialysis subjects, designed to determine whether blood
volume monitoring reduced hospitalization. Logistic
regression was used to estimate the association between BP
changes with hemodialysis (Dsystolic blood pressure¼
postdialysis–predialysis systoic BP (SBP) and the primary
outcome of non-access-related hospitalization and death.
Subjects whose systolic blood pressure fell with dialysis were
younger, took fewer blood pressure medications, had higher
serum creatinine, and higher dry weights. After controlling
for baseline characteristics, lab variables, and treatment
group, subjects whose SBP remained unchanged with
hemodialysis (N¼ 150, DSBP 10 to 10 mm Hg) or whose
SBP rose with hemodialysis (N¼ 58, DSBPX10 mm Hg) had a
higher odds of hospitalization or death compared to subjects
whose SBP fell with hemodialysis (N¼ 230, DSBP p10 mm
Hg) (odds ratio: 1.85, confidence interval: 1.15–2.98; and odds
ratio: 2.17, confidence interval: 1.13-4.15). Subjects whose
systolic blood pressure fell with hemodialysis had a
significantly decreased risk of hospitalization or death at 6
months, suggesting that hemodynamic responses to dialysis
are associated with short-term outcomes among a group of
prevalent hemodialysis subjects. Further research should
attempt to elucidate the mechanisms behind these findings.
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Significant controversy surrounds the issue of hypertension
and outcomes among hemodialysis (HD) patients. Unlike the
general population,1 a direct association between elevated
blood pressure (BP) and cardiovascular mortality has not
been clearly identified in dialysis patients.2–12 Although long-
term studies are required to define the association between
hypertension and outcomes,11 pronounced mortality rates
and the presence of comorbid conditions that contribute to
high mortality among HD patients may limit the ability to
detect an independent association between hypertension and
outcomes.
A number of studies have been published investigating the
associations between BP and outcomes among end-stage
renal disease (ESRD) patients.2–6,8–14 The available observa-
tional studies suggest that the relationship between BP and
outcomes is complex and differs from the general population.
Unfortunately, there are a number of difficulties associated
with studying the association between BP and outcomes
among HD patients. First, it remains unclear which BP
parameter to use in these studies: predialysis, postdialysis,
and intradialytic changes in BP are all available, yet which
parameter is most strongly associated with detrimental
outcomes remains uncertain. Second, clinician’s ability to
change BP is limited in HD patients due to high frequency15
and severity16 of BP, as well as due to changes in BP
associated with interdialytic weight gain, which is directly
related to mortality risk.17–19
Clinically, physicians are carefully balancing the relation-
ship between intradialytic weight loss and BP. In some ESRD
patients, BP is unaffected by ultrafiltration and hemodialysis,
where as other patients experience a more pronounced
hemodynamic response with hemodialysis. Differences in
clinical characteristics between such patient groups have not
been fully described nor has the relationship between BP
responses to ultrafiltration with hemodialysis and outcomes
been characterized to date.20,21
Owing to the complex relationship between BP, weight
gain, and mortality, we postulated that the association
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between hemodynamic changes and outcomes might be
best assessed using other parameters such as hospitali-
zation. Herein, we undertook a secondary analysis of
CLIMB (the Crit-line Intradialytic Monitoring Benefit
Study) to assess whether BP responses to hemodialysis are
associated with differential short-term outcomes while




Baseline characteristics of subjects enrolled in the CLIMB
study have been previously reported.22 Two hundred and
thirty subjects (52.5%) had a fall in systolic blood pressure
(SBP) associated with HD (DSBP p10 mm Hg), 150
subjects (34.2%) did not have a significant change in SBP
from pre- to post-HD (DSBP 10 to 10 mm Hg), and 58
subjects (13.2%) exhibited a paradoxical rise in SBP with HD
(DSBP X10 mm Hg) (Table 1). Subjects whose SBP fell with
HD were younger and were on less antihypertensive
medications. They also had higher predialysis systolic and
diastolic BP, lower postdialysis systolic and diastolic BP,
higher serum creatinine, and higher dry weights. There was a
trend toward a higher prevalence of male subjects and a
higher prevalence of diabetes mellitus among subjects whose
SBP decreased during HD. Subjects whose SBP were
unchanged with dialysis had the lowest prevalence of diabetes
mellitus and the highest rates of catheter use compared to
subjects whose SBP fell with HD or whose SBP rose with HD.
Unadjusted outcomes
During the 6-month follow-up, 132/438 (30.1%) subjects had
a primary event (either non-access-related hospitalization
(N¼ 108) or death (N¼ 5) or both (N¼ 19)) (Table 2).
Compared to subjects whose SBP fell with HD, subjects
whose SBP was unchanged with HD or who had a
paradoxical rise in SBP with HD had an increased risk of
non-access-related hospitalization or death at 6 months
(odds ratio (OR): 1.89, confidence interval (CI): 1.20–2.96,
DSBP: 10 to 10 mm Hg vs DSBP p10 mm Hg; OR: 2.14,
CI: 1.17–3.93, DSBP X10 mm Hg vs DSBP p10 mm Hg,
P¼ 0.0056). Annual non-access-related hospitalization rates
were 0.96 (72.96 hospitalizations/year) among subjects
whose SBP fell with HD compared to 1.55 (73.33) among
subjects whose SBP was unchanged with HD and 1.90
(73.86) among subjects whose SBP rose with HD
(P¼ 0.0083).
When DSBP was modeled as a continuous variable, every
1 mm Hg increase in DSBP following HD was associated with
an increased odds of a non-access-related hospitalization or
death at 6 months (OR: 1.02, CI: 1.01–1.03, P¼ 0.0009).
Thus, a 10 mm Hg increase in SBP with HD was associated
with a 20% increased odds of hospitalization or death at 6
months among subjects. The relationship between 10 mm Hg
increments of DSBP and annual non-access-related hospita-
lization is plotted in Figure 1.
Multivariable analysis
After adjusting for relevant confounders, subjects whose SBP
was unchanged with HD or whose SBP rose with HD had an
increased risk of non-access-related hospitalization or death
compared to patients whose SBP fell with HD (P¼ 0.012)
(Table 3).
In adjusted models with DSBP as a continuous variable,
every 1 mm Hg increase in DSBP following HD was associated
with a 2% increased odds of non-access-related hospitaliza-
tion or death (OR: 1.02, CI: 1.01–1.03, P¼ 0.0022).
In multivariate analyses, other variables associated with an
increased risk of hospitalization or death included lower dry
weight (P¼ 0.018), history of coronary artery disease or
congestive heart disease (P¼ 0.018), CLIMB treatment group
(P¼ 0.033), and increasing phosphorus (P¼ 0.049). There
was a trend toward improved outcomes among black subjects
(P¼ 0.084). Variables not associated with an increased risk of
the primary outcome included increasing age; % of
interdialytic weight gain; dialysis vintage; number of BP
medications; access type; history of arrhythmia, diabetes
mellitus, hypertension, left ventricular hypertrophy, or
peripheral vascular disease; and baseline creatinine, albumin,
calcium, or urea reduction ratio.
DSBP category did not interact with age (P¼ 0.76), race
(P¼ 0.92), % of interdialytic weight gain (P¼ 0.55), history
of coronary artery disease or congestive heart failure
(P¼ 0.25), diabetes mellitus (P¼ 0.42), left ventricular
hypertrophy (P¼ 0.25), peripheral vascular disease
(P¼ 0.33), predialysis SBP (P¼ 0.14), or predialysis diastolic
BP (P¼ 0.999).
Sensitivity analysis
Four separate models were tested, which included the
addition of predialysis systolic and diastolic BP, postdialysis
systolic and diastolic BP, predialysis pulse pressure, and
postdialysis pulse pressure. In each model performed, none
of the BP parameters were associated with an increased risk
of the primary outcome, nor did they significantly modify the
effect of DSBP on outcomes (data not shown).
Further sensitivity analyses were performed, which
excluded subjects without KDOQI-(Kidney Disease Out-
comes Quality Initiative) defined hypertension (predialysis
SBP o140 and postdialysis SBP o130, and predialysis
diastolic o90 and postdialysis diastolic o80). According to
these standards, 343/431 (79%) subjects had hypertension in
our cohort. After adjustment for relevant covariates, DSBP
remained a strong predictor of outcomes among subjects
with KDOQI-defined hypertension (Table 4).
Separate analyses included only subjects on antihyperten-
sive medications to assess the impact of medication class on
outcomes and to determine if specific antihypertensives
modified the effect of DSBP on outcomes. In our cohort, 76%
of subjects were on antihypertensive medications. None of
the classes of antihypertensive agents were associated with the
primary outcome (alpha blocker (P¼ 0.88), angiotensin-
converting enzyme-1 (P¼ 0.30), b blocker (P¼ 0.85),
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Table 1 | Baseline clinical and demographic characteristics of the study population
Systolic blood pressure change (DSBP) associated with hemodialysis
DSBP p10 mm Hg,
n=230
DSBP 10 to 10 mm Hg,
n=150
DSBP X10 mm Hg,
n=58 P-value
Age (years) 57.36 (714.97) 60.34 (716.00) 63.64 (716.54) 0.013
Gender (% male) 55.2% (127/230) 48.0% (72/150) 43.1% (25/58) 0.16
Race (%)
White 55.2% 66.0% 55.2% 0.14
Black 38.3% 28.7% 38.9%
Others 6.5% 5.3% 6.9%
Tobacco use (vs nonuse) 27.9% (63/226) 37.0% (54/146) 28.1% (16/57) 0.16
Hispanic ethnicity (vs non-Hispanic) 3.5% (8/230) 1.3% (2/150) 1.7% (1/58) 0.37
Diabetes mellitus (vs non-DM) 49.1% (113/230) 37.6% (56/149) 46.4% (26/56) 0.083
Diabetes as cause of ESRD (vs others) 33.9% (78/230) 23.3% (35/150) 36.2% (21/58) 0.052
Hypertension 87.4% (201/230) 92.6% (137/148) 87.3% (48/55) 0.24
Antihypertensive medications (vs no antihypertensive use) 73.9% (170/230) 74.7% (112/150) 87.9% (51/58) 0.074
Arrythmia 17.2% (39/227) 18.1% (27/149) 20.7% (12/58) 0.83
Cardiac diseasea 42.8% (98/229) 35.3% (53/150) 43.9% (25/57) 0.30
Chronic obstructive pulmonary disease 10.0% (23/229) 14.9% (22/148) 16.1% (9/56) 0.26
Cerebrovascular disease 20.0% (46/230) 17.5% (26/149) 14.3% (8/56) 0.56
Left ventricular hypertrophy 29.1% (67/230) 22.7% (34/150) 24.1% (14/58) 0.35
Peripheral vascular disease 20.5% (47/229) 19.6% (29/148) 17.9% (10/56) 0.90
Blood pressure (mm Hg)
Predialysis
Systolic 155.46 (718.40) 144.51 (722.45) 139.28 (721.62) o0.0001
Diastolic 82.49 (711.96) 77.19 (713.52) 73.76 (712.17) o0.0001
Postdialysis
Systolic 130.52 (717.26) 142.43 (721.88) 157.92 (720.53) o0.0001
Diastolic 71.30 (711.00) 75.48 (712.90) 79.33 (712.32) o0.0001
DSBP 24.94 (712.69) 2.07 (75.61) 18.64 (78.07) o0.0001
Pulse pressure
Predialysis 72.97 (715.07) 67.32 (715.09) 65.53 (717.29) 0.0004
Postdialysis 59.22 (713.14) 66.96 (715.41) 78.59 (717.61) o0.0001
% of interdialytic weight gain 3.9% (71.28) 3.8% (71.61) 3.7% (71.34) 0.26
Interdialytic weight gain (kg) 3.11 kg (71.07) 2.70 (71.08) 2.62 (71.11) 0.0002
Dry weight (kg) 81.12 (723.07) 73.00 (717.55) 71.45 (716.20) o0.0001
Baseline laboratoryb
Albumin (g/dl) 3.73 (70.49) 3.77 (70.54) 3.72 (70.31) 0.72
Creatinine (mg/dl) 9.68 (73.20) 8.85 (73.28) 8.52 (72.70) 0.012
Calcium (mg/dl) 9.27 (70.96) 9.14 (70.89) 8.96 (70.82) 0.053
Phosphorus (mg/dl) 5.84 (71.81) 5.62 (72.00) 5.48 (71.68) 0.32
PTH, median (pg/ml) 187.0 (64.0–435.0) 193.0 (75.0–382.0) 147.5 (53.3–214.5) 0.44
Cholesterol (mg/dl) 168.80 (746.24) 167.91 (737.70) 171.11 (740.02) 0.95
Hemoglobin (g/dl) 11.42 (71.43) 11.52 (71.33) 11.11 (71.35) 0.18
URR, median 0.72 (0.68–0.76) 0.73 (0.68–0.78) 0.75 (0.71–0.78) 0.04
Number of antihypertensive medications (mean7s.d.) 1.37 (71.14) 1.47 (71.13) 1.79 (71.06) 0.021
Antihypertensive class (% use)
Ace-I 30.0% (69/230) 28.7% (43/150) 32.8% (19/58) 0.85
Alpha-blocker 4.4% (10/230) 6.0% (9/150) 3.5% (2/58) 0.67
Beta-blocker 35.2% (81/230) 31.3% (47/150) 39.7% (23/58) 0.50
CCB 35.2% (81/230) 42.7% (64/150) 44.8% (26/58) 0.22
Diuretic 3.5% (8/230) 3.3% (5/150) 6.9% (4/58) 0.50
Nitrate 11.0% (25/228) 18.7% (28/150) 24.2% (14/58) 0.019
Vasodilator 17.4% (40/230) 16.7% (25/150) 27.6% (16/58) 0.18
Epoetin use (vs nonuse) 89.6% (206/230) 90.0% (135/150) 87.9% (51/58) 0.91
Dialysis vintage
0–1 year 26.6% (60/226) 31.0% (45/145) 25.9% (15/58) 0.60
41 year 73.5% (166/226) 69.0% (100/145) 74.1% (43/58)
Table 1 continued on the following page
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calcium channel blocker (P¼ 0.99), diuretic (P¼ 0.76),
nitrate (P¼ 0.31), or vasodilator (P¼ 0.81)), nor did they
modify the impact of DSBP on outcomes (data not shown).
DISCUSSION
Our study demonstrates that hemodynamic responses
with hemodialysis are associated with short-term clinical
outcomes among a cohort of prevalent dialysis subjects.
Although the effect of hypertension on long-term clinical
outcomes remains uncertain,2–5,7,8,11 in our investigation,
SBP that was unchanged with HD or paradoxically rose with
HD was associated with an increased risk of non-access-
related hospitalization or death at 6 months compared to SBP
that fell with HD. Furthermore, in our investigation, BP
changes associated with hemodialysis were more strongly
associated with clinical outcomes than pre- or postdialysis
systolic BP, diastolic BP, or pulse pressure.
Our study suggests that hemodynamic responses to
dialysis may be used to identify subjects at increased risk of
important short-term events. Although no study to date has
demonstrated this relationship, a recent study by Stidley
et al.9 suggests that the association between BP and outcomes
varies over time. In their investigation of 16 959 incident
hemodialysis patients, elevated predialysis SBP (4160 vs
140–149 mm Hg) was associated with lower mortality, and
low postdialysis SBP (o110 mm Hg) was associated with
increased mortality. However, no models included both
Table 1 | Continued
Systolic blood pressure change (DSBP) associated with hemodialysis
DSBP p10 mm Hg,
n=230
DSBP 10 to 10 mm Hg,
n=150
DSBP X10 mm Hg,
n=58 P-value
Years (median7IQR) 2.17 (0.97–4.02) 1.68 (0.85–3.47) 2.28 (0.96–4.03) 0.25
Access type
AV fistula 35.8% (82/229) 32.9% (49/149) 32.8% (19/58) 0.023
AV graft 44.5% (102/229) 36.9% (55/149) 55.2% (32/58)
Catheter 19.7% (45/229) 30.2% (45/149) 12.1% (7/58)
Treatment Group (vs usual care) 52.2% (120/230) 43.3% (65/150) 46.6% (27/58) 0.23
aCombined history of coronary disease or congestive heart disease.
bSeven subjects were missing baseline albumin, 36 missing creatinine, five missing calcium, five missing phosphorus, 217 missing PTH, 208 missing cholesterol, 59 subjects
missing hemoglobin, and 44 missing URR.
CCB, calcium channel blocker; AV, arteriovenous; URR, urea reduction ratio; PTH, parathyroid hormone.
Note: to convert albumin in g/dl to g/l, multiply by 10; serum creatinine in mg/dl to mmol/l, multiply by 88.4; calcium in mg/dl to mmol/l, multiply by 0.2495; phosphorus in
mg/dl to mmol/l, multiply by 0.3229; PTH in pg/ml to ng/l, multiply by 1; cholesterol in mg/dl to mmol/l, multiply by 0.02586; hemoglobin in g/dl to g/l, multiply by 10.
Table 2 | Unadjusted comparison of 6-month mortality and non-access-related hospitalization rates among prevalent ESRD
subjects grouped by changes in SBP with HDa
Number of subjects with an event (%) Odds ratio (95% CI) P-value
Combined end point of non-access-related hospitalization or death
SBP fell with HD (DSBP p10 mm Hg) 54/230 (23.5%) 1.00 (reference) 0.0056
SBP unchanged with HD (DSBP 10 to 10 mm Hg) 55/150 (36.7%) 1.89 (1.20–2.96)
SBP rose with HD (DSBP X10 mm Hg) 23/58 (39.7%) 2.14 (1.17–3.93)
Non-access-related hospitalizationb
SBP fell with HD (DSBP p10 mm Hg) 53/230 (23.0%) 1.00 (reference) 0.014
SBP unchanged with HD (DSBP 10 to 10 mm Hg) 52/150 (34.7%) 1.77 (1.12–2.79)
SBP rose with HD (DSBP X10 mm Hg) 22/58 (37.9%) 2.04 (1.11–3.77)
Deathb
SBP fell with HD (DSBP p10 mm Hg) 7/230 (3.0%) 1.00 (reference) 0.046
SBP unchanged with HD (DSBP 10 to 10 mm Hg) 11/150 (7.3%) 2.52 (0.96–6.66)
SBP rose with HD (DSBP X10 mm Hg) 6/58 (10.3%) 3.68 (1.19–11.40)
Combined end point of non-access-related hospitalization or death
DSBP (per 1 mm Hg increase) 1.020 (1.01–1.03) 0.0009
aReference is DSBPp10 mm Hg.
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Figure 1 | Unadjusted annual non-access-related hospitalization
rates among prevalent ESRD subjects plotted per 10 mm Hg
increment increase in DSBP (DSBP¼postdialysis–predialysis
SBP).
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pre- and postdialysis SBP to determine whether hemody-
namic responses to dialysis were associated with clinical
outcomes.
Interestingly, Foley et al.2 analyzed pre- and postdialysis
BP parameters in 11 142 prevalent United States Renal Data
System (USRDS) patients and found that neither pre- nor
postdialysis SBP was significantly associated with all-cause
mortality after controlling for demographics, comorbid
conditions, and % of interdialytic weight gain. Their
investigation suggested that wide pulse pressure, potentially
as a marker of vascular compliance, was associated with
increased long-term mortality. Unfortunately, direct compar-
isons between studies are not appropriate given the different
duration of follow-up.
The lack of an association between a variety of other BP
parameters (such as pre- or postdialysis SBP) and clinical
outcomes in our investigation can likely be explained by two
factors: (1) the deleterious effects related to hypertension
likely require longer follow-up than available in the CLIMB
study and (2) recent literature suggests that routine dialysis
BP parameters may not be reflective of the hemodynamic
burden a patient experiences between dialysis treat-
ments.11,23,24 Thus, the lack of a significant association
between other BP parameters and outcomes does not
minimize this relationship, but highlights the importance
of hemodynamic responses associated with HD on outcomes
over short follow-up periods.
The explanation for the association between adverse
outcomes associated with SBP that fails to fall with dialysis
is unclear. Furthermore, the pathophysiology underlying
differential BP responses to dialysis is also unclear. However,
it has been postulated that failure to lower BP with dialysis is
mediated by enhanced renin–angiotensin system and/or
increased sympathetic nervous system activity in response to
decreases in blood volume.25 In addition, underlying cardi-
ovascular disease26 or inability to achieve dry weight has also
been suggested as causing this effect.27,28 Furthermore, failure
to lower BP with HD is also likely independent of vascular
calcification, which would stiffen vessels, reduce compliance,
and increase differences in SBP after volume reduction.29
A number of studies suggest that patients who do not
reach target dry weights may be less likely to respond to HD
with an appropriate lowering of BP.27,28 Fishbane et al.27
compared 21 HD patients and found that atrial natiuretic
peptide levels were significantly higher postdialysis among
patients whose mean arterial pressures (MAP) were un-
changed with HD (DMAPB1 mm Hg) compared to those
whose MAP fell with HD (DMAPB20 mm Hg). Further-
more, successful sequential ultrafiltration with lowering of
dry weight among three patients converted them to having
MAPs that fell with HD and to having lower ANP levels
following HD. In another study of seven patients with an
increase in BP with dialysis and significant cardiac dilation,
intense ultrafiltration over time normalized BP responses and
cardiac parameters in most patients.28
Mourad et al.26 analyzed pulse-wave velocity among ESRD
patients whose MAP increased 6% with dialysis compared to
those whose MAP fell 17% with dialysis, and found that
mean pulse-wave velocity was significantly higher among
patients whose MAP increased with HD. Prior investiga-
tions have found a strong relationship between increasing
pulse-wave velocity and higher mortality among ESRD
Table 3 | Adjusted analysis of 6-month mortality and non-access-related hospitalization among prevalent ESRD subjectsa
Variable Odds ratio (95% CI) P-value
SBP fell with HD (DSBP p10 mm Hg) 1.00 (reference) 0.012
SBP unchanged with HD (DSBP 10 to 10 mm Hg) 1.85 (1.15–2.98)
SBP rose with HD (DSBP X10 mm Hg) 2.17 (1.13–4.15)
Dry weight (per 1 kg increase) 0.99 (0.97–1.00) 0.018
Cardiac disease (yes vs no) 1.70 (1.10–2.64) 0.018
Treatment group (treatment vs usual care) 1.62 (1.04–2.51) 0.033
Phosphorus (per 1 mg/dl increase) 1.12 (1.001–1.26) 0.049
Black race (vs non-black race) 0.65 (0.40–1.06) 0.084
aVariables tested for significance included the following: age; race; dry weight; % of interdialytic weight gain; DSBP; dialysis vintage; access type; history of arrhythmia, cardiac
disease (coronary artery disease or congestive heart disease), diabetes mellitus, hypertension, left ventricular hypertrophy, and peripheral vascular disease; baseline albumin,
creatinine, calcium, phosphorus, and urea reduction ratio; number of BP medications; and treatment group.
Table 4 | Combined outcome of 6-month mortality and non-access-related hospitalization among hypertensive (defined by
KDOQI standards) ESRD subjects (N=343/431)
Adjusted odds ratio (95% CI)a P-value
SBP fell with HD (DSBP p10 mm Hg) 1.00 (reference) 0.006
SBP unchanged with HD (DSBP 10 to 10 mm Hg) 2.08 (1.19–3.61)
SBP rose with HD (DSBP X10 mm Hg) 2.61 (1.29–5.27)
DSBP (per 1 mm Hg increase) 1.02 (1.01–1.04) 0.001
aControlled for black race, cardiac disease, baseline phosphorus, dry weight, and treatment group.
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patients.30,31 These studies suggest that possibly under-
diagnosed larger artery vascular disease may play a role in
the poorer outcomes noted among subjects whose BP failed
to fall with dialysis.
Although the findings of this study are novel, this analysis
is not without limitations. For example, owing to sample size
and missing data, the associations between cholesterol,
hemoglobin, and parathyroid harmone and clinical outcomes
could not be assessed. Although these parameters may have
an effect on arterial compliance, there were no significant
differences in the baseline values between groups based on
DSBP, suggesting that these parameters may not have altered
our analyses. Second, given the observational nature of the
present study, no conclusions regarding cause and effect can
be made. Third, the BP parameters used for this analysis were
not standardized and were obtained from an average of four
dialysis sessions; however, prior studies have used 1 week
averages of routine dialysis BP recordings to assess out-
comes,2,4 and routine dialysis BP parameters are more useful
to apply to clinical practice. Fourth, the subjects included in
these analyses were prevalent to hemodialysis. Given the
known high mortality and morbidity among incident ESRD
patients, our cohort likely represents a healthier patient
population who survived the initial dialysis period. In
addition, the cohort utilized for this analysis was part of a
randomized controlled trial, which excluded ‘sicker patients’
(such as those with low serum albumin), and the known
volunteer bias likely resulted in the lower than expected
mortality in this cohort. These factors likely affect the
generalizability of our results to the wider range of prevalent
ESRD patients and caution should be used in applying these
results to the broader USRDS population.
Hemodynamic responses to hemodialysis are associated
with short-term outcomes among a cohort of prevalent
hemodialysis subjects. Failure to lower SBP with HD was
associated with a significantly increased risk of non-access-
related hospitalization and death at 6 months in our analysis,
which was independent of weight gain and similar among
patients taking or not taking antihypertensives. Further
research should seek to identify the underlying pathophysiol-
ogy behind differential hemodynamic responses with dialysis
among ESRD patients in order to try to identify modifiable
risk factors to target for interventions in this high-risk group.
MATERIALS AND METHODS
Patient population
Subjects for this analysis included 443 patients who were enrolled in
the CLIMB study.22 Methods, baseline characteristics, and the results
of the CLIMB study have been previously reported.22 Entry criteria
included age between 18 and 85 years, ESRD duration for X2
months, and treatment with in-center hemodialysis three times a
week. Exclusion criteria included BP not measurable by standard
techniques, active gastrointestinal bleed, severe malnutrition (albu-
min o2.6 g/dl), active hematologic disease, patient expected to be
unavailable due to moving or living donor renal transplant,
malignancy requiring chemotherapy, and inability to provide
informed consent. The Institutional Review Board at each of the
six participating centers approved the original study protocol and the
Duke University Institutional Review Board approved this analysis.
Outcomes
The primary end point of the original CLIMB study was non-access-
related hospitalization. For the purpose of this analysis, the primary
end point is a combined outcome of non-access-related hospitaliza-
tion and death at 6 months. Annual non-access-related hospitaliza-
tion rates and 6-month mortality were also analyzed separately in
secondary analyses.
Study measurements
Subjects enrolled in CLIMB were observed for 2 weeks and then
randomized to 6 months of intradialytic blood volume monitoring
using Crit-Line* (Hema Metrics Inc. (*formerly In-Line Diagnos-
tics), Kaysville, UT, USA) or conventional clinical strategies. Subjects
were subsequently followed for 6 months.
At enrollment, the following baseline parameters were obtained
and were available for this analysis: demographics (race, age, sex);
dialysis vintage; tobacco use (defined as current or quit within last
10 years); dialysis access type; treatment center; past medical history
including history of diabetes mellitus, cause of ESRD (diabetes
mellitus, hypertension or other), hypertension, bilateral nephrect-
omy, peripheral vascular disease, chronic obstructive pulmonary
disease, coronary artery disease (defined as a history of myocardial
infarction, coronary artery bypass graft, or percutaneous coronary
intervention), congestive heart failure (defined as a history of
congestive heart disease or left ventricular dysfunction), left
ventricular hypertrophy (defined by the presence of left ventricular
hypertrophy on echocardiography or electrocardiogram), cerebro-
vascular disease (history of transient ischemic attach or stroke),
arrythmia (cardiac arrest, atrial fibrillation/flutter, atrial/ventricular
tachycardia, or ventricular fibrillation), malignancy, antihyperten-
sive medication class, and routine laboratory data.
Subjects were seen thrice weekly during routine hemodialysis and
the following values were recorded and available for the analysis:
pre- and postdialysis BP sitting and standing, lowest BP during
treatment, pre- and postdialysis weight, target dry weight (deter-
mined by the treating nephrologists), intradialytic interventions,
and complications.
Definitions
Baseline BP and weight gain parameters used for this analysis were
averaged from preintervention and the first week of the study and
included four dialysis sessions (1 mid-week dialysis session at
preintervention and three dialysis sessions during the first week in
the study). BP parameters were obtained by automated devices by
dialysis nurses trained at each individual dialysis unit. The following
definitions were used:
K % of interdialytic weight gain¼ ((predialysis weight
(kg)–previous postdialysis weight (kg))/target dry weight
(kg)) 100.18,19,32,33
K Interdialytic weight gain¼ predialysis weight (kg)–pre-
vious postdialysis weight (kg).
K DSBP¼ sitting postdialysis SBP–sitting predialysis SBP at
the same dialysis treatment session.
K Annualized hospitalization rate¼ (no. of hospitalizations/
number of person days) 365 days/year.
For the purpose of this study, subjects were divided a priori
into three clinical groups based on BP changes with HD: (1)
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SBP fell with HD (DSBP p 10 mm Hg) (2) SBP unchanged with
HD (DSBP 10 to 10 mm Hg), and (3) SBP rose with HD (DSBP
X10 mm Hg).
Statistical analysis
Of the 443 subjects initially enrolled in the CLIMB study, one
subject was excluded owing to lack of follow-up after enrollment
and four subjects were excluded owing to missing pre- or
postdialysis BP recordings during enrollment and the first week of
the study. The remaining 438 subjects were included in unadjusted
analysis. Owing to missing data in seven of these subjects, 431
subjects were included in the final multivariable model.
Descriptive statistics are presented as counts and percentages for
discrete variables. Continuous variables are reported as means with
standard deviations unless noted otherwise. Categorical variables
were compared with w2 tests. One-way analysis of variance was used
to compare normally distributed continuous variables; otherwise,
the non-parametric Kruskal–Wallis test (for three-way comparisons)
was used.
In unadjusted analysis, logistic regression was utilized to
compare differences in clinical outcomes between patients grouped
by DSBP. All event analyses used logistic regression rather than
survival methodology because of the short duration of follow-up
and concerns associated with violating proportional hazards
assumptions in Cox proportional hazards models. For the primary
outcome, only one event per subject was included as an end point.
The relationship between DSBP and clinical outcomes was also
modeled separately as a continuous variable.
In adjusted analysis, logistic regression was used to determine
the relationship between DSBP and outcomes while controlling
for demographics and case-mix. Backward selection was used to
identify the final multivariable model. Owing to our small
sample size and limited number of clinical events, only parameters
deemed clinically relevant or significantly different between
groups were initially entered into the full model. Variables with a
large number of missing data were not tested for inclusion
unless they trended toward a difference among groups (Po0.15).
Variables tested in the final model included age; race; dry
weight; % of interdialytic weight gain; DSBP; dialysis vintage;
access type; history of arrhythmia, cardiac disease (coronary
artery disease or congestive heart disease), diabetes mellitus,
hypertension, left ventricular hypertrophy, and peripheral vascular
disease; baseline albumin, creatinine, calcium, phosphorus, and
urea reduction ratio; number of BP medications; and treatment
group. Variables that were not significant with a P-value 40.10 in
the model were removed until only variables with a P-value o0.10
remained. Treatment group was forced into all models. To assess
for potential confounding, separate models were tested to
examine whether other hemodynamic parameters (pre- or post-
dialysis SBP, diastolic BP, or pulse pressure) modified the effect
of DSBP on outcomes or were significantly associated with
outcomes. Interaction terms between prespecified parameters and
DSBP were also tested.
Sensitivity analyses that assessed the relationship between DSBP
and outcomes only among patients with KDOQI-defined hyperten-
sion (predialysis sitting BPX140/90 or postdialysis sitting BPX130/
80)34 and separately only among patients on antihypertensive
medications were performed. Subsequently, the ability of specific
antihypertensive agents to modify the effect of DSBP on outcomes
among patients on antihypertensive agents or were independently
associated with the primary outcome was tested.
All statistical analyses were performed using SAS Eguide (version
9.1, SAS Institute, Cary, NC, USA).
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